A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Brief description of study
The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab (a PD-L1 inhibitor) or tremelimumab (a CTLA-r inhibitor) in participants with advanced solid tumors.
Clinical Study Identifier: s16-00039
ClinicalTrials.gov Identifier: NCTs16-00039
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
